References

Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study

10.1002/acr.24786 · 2023 · External reference

Risk of Malignancy in Dermatomyositis and Polymyositis

10.1177/1203475416665601 · 2017 · External reference

10.1038/s41584-023-01045-w

10.1038/s41584-023-01045-w · External reference

Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis

10.2340/00015555-3091 · 2019 · External reference

10.1177/014107688507800915

10.1177/014107688507800915 · External reference

10.1097/01.smj.0000215732.28409.af

10.1097/01.smj.0000215732.28409.af · External reference

Amyopathic dermatomyositis associated with esophageal cancer

10.1111/j.1365-4632.2008.03486.x · 2008 · External reference

Cancer-associated myositis associated with oesophageal adenocarcinoma arising in Barrett’s oesophagus without serum myogenic enzymes elevation: an example suggesting the importance of MRI

10.1136/bcr-2016-215047 · 2016 · External reference

Dermatomyositis as a paraneoplastic phenomenon in oesophageal cancer

10.1136/bcr-2018-227387 · 2018 · External reference

A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients

10.12659/ajcr.922004 · 2020 · External reference

Unveiling the complex nexus: dermatomyositis and esophageal adenocarcinoma—a case report

10.21037/aoe-23-23 · 2024 · External reference

Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis

10.3389/fimmu.2021.803410 · 2021 · External reference

10.1136/annrheumdis-2017-211468

10.1136/annrheumdis-2017-211468 · External reference

Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature

10.1016/j.autrev.2023.103375 · 2023 · External reference

Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review

10.1093/mrcr/rxad007 · 2023 · External reference

10.1002/art.38093

10.1002/art.38093 · External reference

10.1056/nejmra1402225

10.1056/nejmra1402225 · External reference

Inflammatory Myopathies

10.1056/nejmra2415426 · 2026 · External reference

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study

10.1001/jamaoncol.2018.5441 · 2019 · External reference

10.1200/jco.20.01888

10.1200/jco.20.01888 · External reference